Silence Therapeutics
SLN
65 hedge funds and large institutions have $168M invested in Silence Therapeutics in 2024 Q4 according to their latest regulatory filings, with 16 funds opening new positions, 24 increasing their positions, 13 reducing their positions, and 20 closing their positions.
85% more repeat investments, than reductions
Existing positions increased: 24 | Existing positions reduced: 13
2.41% less ownership
Funds ownership: 20.14% → 17.73% (-2.4%)
6% less funds holding
Funds holding: 69 → 65 (-4)
20% less first-time investments, than exits
New positions opened: 16 | Existing positions closed: 20
40% less funds holding in top 10
Funds holding in top 10: 5 → 3 (-2)
66% less capital invested
Capital invested by funds: $493M → $168M (-$325M)
93% less call options, than puts
Call options by funds: $3K | Put options by funds: $45K
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Morgan Stanley
New York
|
+$12.2M |
| 2 |
NCM
Nantahala Capital Management
New Canaan,
Connecticut
|
+$11M |
| 3 |
RG
Redmile Group
San Francisco,
California
|
+$6.45M |
| 4 |
Bank of America
Charlotte,
North Carolina
|
+$6.43M |
| 5 |
Marshall Wace
London,
United Kingdom
|
+$4.14M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Janus Henderson Group
London,
United Kingdom
|
-$19.8M |
| 2 |
DTC
Deep Track Capital
Greenwich,
Connecticut
|
-$18.2M |
| 3 |
PCH
Polar Capital Holdings
London,
United Kingdom
|
-$18.2M |
| 4 |
LOAMU
Lombard Odier Asset Management (USA)
New York
|
-$10.4M |
| 5 |
Millennium Management
New York
|
-$8.22M |
SLN Hedge Fund Activity: Q4 2024 in Review
65 of the 7,592 institutional investors tracked by Wall St. Rank reported a position in Silence Therapeutics (SLN) for Q4 2024, worth a combined $168M — down 66% from $493M a quarter earlier.
Sellers outnumbered buyers: 20 funds closed out of SLN and 16 opened new positions — a net loss of 4 holders — while 13 trimmed existing stakes and 24 added.
The largest buyer was Morgan Stanley, adding an estimated $12.2M. The largest seller was Janus Henderson Group, exiting entirely with an estimated $19.8M sold.
- 65 institutional investors held Silence Therapeutics (SLN) as of Q4 2024, down from 69 in Q3 2024.
- Funds reported $168M of Silence Therapeutics stock for Q4 2024, down 66% quarter-over-quarter.
- 16 funds opened new Silence Therapeutics positions in Q4 2024 and 20 closed out, a net change of -4 holders.
- The largest Silence Therapeutics buyer in Q4 2024 was Morgan Stanley, an estimated $12.2M added.
- The largest Silence Therapeutics seller in Q4 2024 was Janus Henderson Group, an estimated $19.8M sold.
Based on aggregated 13F filings for Q4 2024.